Interpretation of associations in pharmacoepidemiology

被引:3
作者
Kaufman, David W. [1 ]
机构
[1] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA
关键词
D O I
10.1053/j.seminhematol.2008.04.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pharmacoepidemiology is an important tool for understanding and documenting the relationships between the use of drugs and adverse events. Side effects are an important consideration for clinicians making treatment decisions, and they also figure prominently in action by regulatory agencies. Unlike the results of randomized trials, epidemiologic findings are based on observational data subject to various types of bias; on the other hand, epidemiology has the advantage of monitoring "real world" situations. This chapter is intended to provide readers with a practical treatment of the issues that are encountered in the pharmacoepidemiology literature so that they can arrive at their own interpretation of the findings. The discussion is focused on issues that are of particular relevance to the epidemiologic study of drug associations with hematologic outcomes, including validity of exposure information, appropriate definition of exposure, confounding by indication and from concomitant use of multiple drugs, sample size considerations, and the relationship between size of an association and rarity of the outcome.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 43 条
[31]   Antihypertensive drugs and the risk of idiopathic aplastic anaemia [J].
Myers, MW ;
Vasilakis, C ;
Kaufman, MR ;
Jick, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (06) :604-608
[32]   Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies [J].
Papanikolaou, PN ;
Christidi, GD ;
Ioannidis, JPA .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (05) :635-641
[33]  
Rothman K. J., 1998, MODERN EPIDEMIOLOGY
[34]  
Shapiro S, 2000, AM J EPIDEMIOL, V151, P939, DOI 10.1093/oxfordjournals.aje.a010135
[35]  
Strom BL, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P3
[36]  
Suissa S, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P811
[37]  
TREVETT AJ, 1992, PAPUA NEW GUINEA MED, V35, P210
[38]   LEUKEMIA RISK FOLLOWING HODGKINS-DISEASE - RELATION TO CUMULATIVE DOSE OF ALKYLATING-AGENTS, TREATMENT WITH TENIPOSIDE COMBINATIONS, NUMBER OF EPISODES OF CHEMOTHERAPY, AND BONE-MARROW DAMAGE [J].
VANLEEUWEN, FE ;
CHORUS, AMJ ;
VANDENBELTDUSEBOUT, AW ;
HAGENBEEK, A ;
NOYON, R ;
VANKERKHOFF, EHM ;
PINEDO, HM ;
SOMERS, R .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (05) :1063-1073
[39]  
Vardiman James W, 2006, Hematology Am Soc Hematol Educ Program, P199
[40]   Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002 - The importance of reporting suspected reactions [J].
Wysowski, DK ;
Swartz, L .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (12) :1363-1369